<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252161</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0501</org_study_id>
    <secondary_id>C000000279</secondary_id>
    <nct_id>NCT00252161</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer</brief_title>
  <official_title>Randomized Phase III Trial of Surgery Plus Neoadjuvant TS-1 and Cisplatin Compared With Surgery Alone for Type 4 and Large Type 3 Gastric Cancer: Japan Clinical Oncology Group Study (JCOG 0501)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate survival benefit of TS-1 plus cisplatin as a neoadjuvant
      chemotherapy in gastric cancer patient with resectable type 4 (linitis plastica type) and
      large type 3 tumor in comparison with surgery alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized phase III study is going to started in Japan to compare TS-1 plus cisplatin as a
      neoadjuvant chemotherapy with surgery alone in patient with type 4 and large type 3 gastric
      cancer.A total of 300 patients will be accrued for this study from 35 institutions within
      five years. The primary endpoint is overall survival. The secondary endpoints are progression
      free survival (PFS), response rate, proportion of protocol achievement, proportion of
      curative resection, and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of protocol achievement</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of curative resection</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">316</enrollment>
  <condition>Gastric Neoplasm</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure/Surgery: Gastrectomy with more than D2 dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy with more than D2 dissection</intervention_name>
    <description>Gastrectomy with more than D2 dissection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy</intervention_name>
    <description>Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically proven adenocarcinoma of stomach

          2. Borrmann type 4 or large (&gt;=8 cm) type 3

          3. no evidence of distant metastasis including liver(M0)

          4. no evidence of para-aortic and/or retropancreatic lymph node metastasis(N0-2)

          5. no peritoneal metastasis and negative peritoneal lavage cytology (PLS) with
             laparoscopic confirmation

          6. no involvement of the esophagus with &gt; 3cm

          7. an age of 20-75 years

          8. an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          9. no prior chemotherapy, radiotherapy for any malignancy

         10. no prior surgery for gastric cancer except for endoscopic membrane resection (EMR)

         11. no breeding from primary tumor or gastrointestinal stenosis

         12. sufficient oral intake

         13. adequate organ function

         14. written informed consent

        Exclusion Criteria:

          1. synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          2. pregnant or breast-feeding women

          3. severe mental disease

          4. systemic administration of corticosteroids, flucytosine, phenytoin or warfarin

          5. other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary
             fibrosis, or ischemic heart disease

          6. myocardial infarction within six disease-free months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuru Sasako, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hyogo College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya,Chikusa-ku,Kanokoden,1-1</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University</name>
      <address>
        <city>Toyoake,Kutsukake-cho,Dengakugakubo,1-98</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa,Kashiwanoha,6-5-1</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama,Horinouchi,13</city>
        <state>Ehime</state>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital</name>
      <address>
        <city>Gifu,Kashima-cho,7-1</city>
        <state>Gifu</state>
        <zip>500-8323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hospital</name>
      <address>
        <city>Hiroshima,Naka-ku,Motomachi,7-33</city>
        <state>Hiroshima</state>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itami City Hospital</name>
      <address>
        <city>Itami,Koyaike,1-100</city>
        <state>Hyogo</state>
        <zip>664-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka,Uchimaru,19-1</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University,Faculty of Medicine</name>
      <address>
        <city>Kagoshima,Sakuragaoka,8-35-1</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama,Asahi-ku,Nakao,1-1-2</city>
        <state>Kanagawa</state>
        <zip>241-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Second Red Cross Hospital</name>
      <address>
        <city>Kamigyo-ku,Kamanza-Marutamachi,355-5</city>
        <state>Kyoto</state>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Natori,Medeshima-Shiode,Nodayama,47-1</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization, Sendai Medical Center</name>
      <address>
        <city>Sendai,Miyagino-ku,Miyagino,2-8-8</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaoka Chuo General Hospital</name>
      <address>
        <city>Nagaoka,Kawasaki,2041</city>
        <state>Niigata</state>
        <zip>940-8653</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata,Kawagishi-cho,2-15-3</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsubame Rosai Hospital</name>
      <address>
        <city>Tsubame,Sawatari,633</city>
        <state>Niigata</state>
        <zip>959-1228</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oita University Fuculty of Medicine</name>
      <address>
        <city>Oita,Hasama-machi,Oogaoka,1-1</city>
        <state>Oita</state>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka National Hospital</name>
      <address>
        <city>Osaka,Chuo-ku,Hoenzaka,2-1-14</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka,Higashinari-ku,Nakamichi,1-3-3</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osaka-Sayama,Ohno-higashi,377-2</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakai Municipal Hospital</name>
      <address>
        <city>Sakai,Minamiyasuicho,1-1-1</city>
        <state>Osaka</state>
        <zip>590-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College</name>
      <address>
        <city>Takatsuki,Daigakucho,2-7</city>
        <state>Osaka</state>
        <zip>569-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyonaka Municipal Hospital</name>
      <address>
        <city>Toyonaka,Shibaharacho,4-14-1</city>
        <state>Osaka</state>
        <zip>560-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-adachi,Ina,Komuro,818</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Defense Medical College</name>
      <address>
        <city>Tokorozawa,Namiki,3-2</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka General Hospital</name>
      <address>
        <city>Shizuoka,Aoi-ku,Kitaando,4-27-1</city>
        <state>Sizuoka</state>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital</name>
      <address>
        <city>Bunkyo-ku,Honkomagome,3-18-22</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital</name>
      <address>
        <city>Bunkyo-ku,Yushima,1-5-45</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku,Tsukiji,5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital</name>
      <address>
        <city>Koto-ku,Ariake,3-10-6</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center of Japan</name>
      <address>
        <city>Shinjuku-ku,Toyama,1-21-1</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Bokutoh Hospital</name>
      <address>
        <city>Sumida-ku,Koutoubashi,4-23-15</city>
        <state>Tokyo</state>
        <zip>130-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Central Hospital</name>
      <address>
        <city>Toyama,nishinagae,2-2-78</city>
        <state>Toyama</state>
        <zip>930-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University, School of Medicine</name>
      <address>
        <city>Wakayama,Kimiidera,811-1</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata Prefectural Central Hospital</name>
      <address>
        <city>Yamagata,Aoyagi,1800</city>
        <state>Yamagata</state>
        <zip>990-2292</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>S-1(combination)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

